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Taigo Kato, Keigo Madono, Go Tanigawa,
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We analyzed 95 patients with renal pelvic and ureteral cancers with total nephroureterectomy at our
Department from January, 1997 to April, 2007. The patients were composed of 60 males and 35 females,
between 41 and 90 years old with a median age of 69 years old. Histologically, there were 94 transitional
cell carcinomas (TCC) and 1 TCC with squamous cell carcinoma. Fifty ﬁve cases (57.9%) were less than
pT2, and 41 cases (42.1%) were more than pT3. Findings of lymphatic and venous invasion were present in
35 cases and 24 cases respectively. The overall survival rate at 5 years was 76.6%. In this series,
pathological stage, inﬁltration pattern, lymphatic and/or venous invasion and the regional lymph nodes
indicated a signiﬁcantly poor prognosis. On the other hand, multivariate analysis using Cox proportional
hazards regression revealed the presence of pathological stage as the most signiﬁcant predictor of survival.
Furthermore, we investigated histopathological prognostic factors of the patients separating asymptomatic
macrohematuria group (AM group) and non-asymptomatic macrohematuria group (non-AM group).
According to this analysis, non-AM group had worse pathological stage, grade and lymphatic invasion than
AM group.
(Hinyokika Kiyo 55 : 59-63, 2009)



















差検定には log-rank test を用いた．独立性の検定には
χ
2 検定を用い，予後因子の多変量解析には Cox の比
例ハザードモデルを用いた．なお統計プログラムは
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傾向にあり，また grade が高くなると尿細胞診陽性率
が60.1，67.1，82.6％と高くなる傾向にあった．深達







(pL），壁内静脈侵襲 (pV) の関係を Table 2 に示し
た．pT2 以上の浸潤癌は pT1 以下の表在癌より INFγ



















検討したところ，pT2 以下と pT3 以上，INFα，β と









pT，INF，pL，pV の risk ratio はそれぞれ 3.127，
1.287，2.229，2.584であり，深達度が有意に独立し
た予後因子であった (p＝0.0205) (Table 4）．
6．術後補助療法と再発転移
術後化学療法に関しては一定のプロトコールを設定
していなかったが，原則的に pT2 以上で G3 または
INFγ，pL1，pV1 のいずれかを要する症例に対して
行っ た．補 助 化 学 療 法 は MVAC が 31 例，CPA
(CDDP，ADM，CPA) が 1 例であった．リンパ節転
移陽性例12例を除く pT3 もしくは pT2 で壁内リンパ
管侵襲，壁内静脈侵襲のいずれかを認めた38例におい








Asymptomatic macrohematuria 60 (63.8％)
Flank pain or abdominal pain 16
Microscopic hematuria 7
Follow-up for bladder cancer 3











Pelvis and ureter 2
Cytology
Positive (class IV, V) 60 (65.2％)
Suspicious (class III) 19
Negative (class I, II) 13
Unknown 3
Table 2. Relationship between pT and other pathological factors
No G1 G2 G3 INFα INFβ INFγ pL0 pL1 pV0 pV1
pTis 9 3 1 5 7 2 0 9 0 9 0
pTa 20 10 8 2 16 4 0 19 1 19 1
pT1 16 1 12 3 7 9 0 13 3 15 1
pT2 9 1 6 2 1 8 0 5 4 9 0
pT3 37 1 28 8 7 26 4 14 23 19 18
pT4 4 0 1 3 0 2 2 0 4 0 4
Total 95 16 56 23 38 51 6 60 35 71 24








リンパ節転移 1例，肺転移 6例，骨転移 2例，肝転移






































Fig. 1. Cause-speciﬁc survival rate of all patients.










Tumor site Pelvis/ureter 89.8/73.7 p＝0.124





Grade G1-2/G3 83.1/68.1 p＝0.160
Stage pTis-2/pT3-4 89.1/58.2 p＜0.005*
Lymphatic
invasion pL0/pL1 91.8/51.2 p＜0.05*
Venous invasion pV0/pV1 81.8/62.1 p＜0.05*
Inﬁltration
pattern INFα, β/lNFγ 79.0/62.5 p＜0.05*
Lymph node






Table 4. Multivariate analysis (Cox proportional hazard model) of prognostic factors for survival
Prognostic factor
Category
Risk ratio 95％ Cl p value
Advantage Disadvantage
Stage Less than pT2 More than pT3 3.127 1.192-8.203 p＝0.0205*
Inﬁltration pattern INFα or β INFγ 1.287 0.047-3.471 p＝0.6188
Lymphatic invasion pL0 pL1 2.229 0.948-5.245 p＝0.0662
Venous invasion pV0 pV1 2.584 1.158-5.768 p＝0.080
































































腫瘍の合併 (n＝32) の 5年生存率が76.4％，合併な








Fig. 2. Bladder tumor recurrence-free curve of all
patients after nephroureterectomy.
泌55,02,01-3
Fig. 3. Survival rate according to the presence of
asymptomatic macrohematuria.
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